Biotechnology · Healthcare
CEO, Board Member
2024-10-24–present
Board Member
Moleculin Biotech, Inc. (MBRX)Equibles does not estimate personal net worth.
Get an email with a short summary when Moleculin Biotech, Inc. publishes a filing, an earnings call transcript or a press release.
Get MBRX alertsWalter V. Klemp is recorded as Board Member at Moleculin Biotech, Inc. (MBRX) since October 24, 2024 and CEO at Moleculin Biotech, Inc. (MBRX). The newest filing on record that lists Walter V. Klemp as CEO at Moleculin Biotech, Inc. (MBRX) is dated August 24, 2026. Moleculin Biotech, Inc. reported in an 8-K filed October 25, 2024 that Walter V. Klemp was appointed Director, effective October 24, 2024. The proxy statement of Moleculin Biotech, Inc. reports total compensation of $1,345,958 for Walter V. Klemp in fiscal 2025, including a base salary of $565,000. Disclosed compensation is on record for 8 fiscal years. Walter V. Klemp has spoken on 9 earnings calls and 1 other investor event across 1 company, most recently for Moleculin Biotech, Inc. on September 11, 2026. Moleculin Biotech, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Moleculin Biotech, Inc. includes Jonathan Foster (CFO), Elizabeth A. Cermak (Board Member), Elizabeth Cermak (Board Member) and 3 others.
“The Company's stockholders elected Walter V. Klemp, Robert E. George, Michael D. Cannon, John Climaco, Elizabeth A. Cermak, and Joy Yan to serve until the 2025 Annual Meeting of Stockholders, or until such person's successor is qualified and elected.”
“Before we start, a reminder that Moleculin is publicly listed, and I'll be making forward-looking statements. Our latest information and SEC filings are on our website at Moleculin.com. Let me start with the punchline because everything that follows supports this page.”
“For most of our investors, the focus is on the Phase 3 MIRACLE trial, studying Annamycin for the treatment of relapsed and refractory acute Myeloid Leukemia. And with good reason.”
“Well, investors who have been following our presentations are not new to this, but we are resolute in our belief that our current market cap is nowhere close to reflecting the value of a Phase 3 company like Moleculin.”
“Calling 2024 transformational for Moleculin would be a massive understatement. We've now been able to lock in composition of matter patent protection for annamycin, giving us market exclusivity at least through 2040.”
“We have some very exciting progress to talk about today. And because of that, we will primarily focus on our AML second-line strategy and the significant opportunity we believe this represents.”
2024-10-24–present
Start not stated–present
Last confirmed August 24, 2026
Biotechnology · Healthcare
CEO, Board Member
2024-10-24–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Moleculin Biotech, Inc. (MBRX) | Chairman, President - Chief Executive Officer | $565,000 | $1,345,958 |
| 2024 | Moleculin Biotech, Inc. (MBRX) | CEO | $565,000 | $1,458,759 |
| 2023 | Moleculin Biotech, Inc. (MBRX) | CEO | $565,000 | $1,414,598 |
| 2022 | Moleculin Biotech, Inc. (MBRX) | CEO | $565,000 | $1,971,080 |
| 2021 | Moleculin Biotech, Inc. (MBRX) | CEO | $537,917 | $1,987,313 |
| 2020 | Moleculin Biotech, Inc. (MBRX) | CEO | $500,000 | $1,516,779 |
| 2019 | Moleculin Biotech, Inc. (MBRX) | CEO | $625,000 | $1,801,716 |
| 2018 | Moleculin Biotech, Inc. (MBRX) | CEO | $402,500 | $1,345,675 |